Women who are pregnant and will be admitted to the hospital for at least 72 hours may be eligible to participate in this trial.
The study is being conducted to investigate the safety and efficacy of two dose of unfractionated heparin that are currently recommended for prophylactic anticoagulation in pregnancy:
Pregnant patients who are hospitalized for a prolonged period of time are at an increased risk of developing a venous thromboembolism (e.g., a clot in your legs or lung). Because of this increased risk, it is recommended to place pregnant patients who are hospitalized for at least 72 hours on prophylactic anticoagulation (e.g., low dose preventive blood thinner) with unfractionated heparin (e.g., medication to slow the formation of blood clots) to prevent the development of clots. Not enough research has been done to determine the best dosing for unfractionated heparin in pregnancy.
Participants must meet the following criteria to be eligible for the trial:
If you’ve answered yes to all the above questions, please
Email: [email protected] or Call: (310) 825-5255
Once in the study, participants will be randomized (like flipping a coin) to one of two dose of unfractionated heparin. Participants in group 1 will receive the standard dose of unfractionated heparin (5,000 units subcutaneous injection every 12 hours). Participants in group 2 will receive the gestational age-based dose of unfractionated heparin (1st trimester or less than 14 weeks of gestation: 5,000 units subcutaneous injection every 12 hours, 2nd trimester or 14-28 weeks of gestation: 7,500 units subcutaneous injection ever 12 hours, 3rd trimester or greater than 28 weeks of gestation: 10,000 units subcutaneous injection every 12 hours). All arms will be open-label. Participants will continue to receive the study dose of the treatment throughout their antepartum hospitalization, until discharge or delivery. Serial lab measurements will be performed and the dose of unfractionated heparin will be adjusted or held per the study protocol to ensure safety.
All participants enrolled in the study will undergo the following testing:
UCLA Protocol ID: IRB#20-001799